Carisma Therapeutics Inc
NASDAQ:CARM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Carisma Therapeutics Inc
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2014-02-06. The firm is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The firm's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2014-02-06. The firm is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The firm's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.
